{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:23:46Z","timestamp":1793258626572,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Second Hospital of Shanxi Medical University Doctoral Fund Project","award":["202201-2"],"award-info":[{"award-number":["202201-2"]}]},{"name":"The Second Hospital of Shanxi Medical University Scientific and Technological Activities of Overseas Students Merit Grant","award":["2020041"],"award-info":[{"award-number":["2020041"]}]},{"name":"the Special Project of Wu Jieping Medical Foundation","award":["320.6750.2022-8-4"],"award-info":[{"award-number":["320.6750.2022-8-4"]}]},{"name":"The Second Hospital of Shanxi Medical University Scientific Research Grant Project for Returned Overseas Students","award":["2021-171"],"award-info":[{"award-number":["2021-171"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02106-6","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T13:52:08Z","timestamp":1772977928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of macrophages and cytokines in the occurrence and development of MDS"],"prefix":"10.1007","volume":"26","author":[{"given":"Peichun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiakai","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongWei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanggang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"key":"2106_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106939","volume":"88","author":"L Li","year":"2020","unstructured":"Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Yu Cai. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88:106939.","journal-title":"Int Immunopharmacol"},{"key":"2106_CR2","doi-asserted-by":"publisher","first-page":"155836","DOI":"10.1016\/j.cyto.2022.155836","volume":"152","author":"J Nata\u0161a Todorovi\u0107-Rakovi\u0107","year":"2022","unstructured":"Nata\u0161a Todorovi\u0107-Rakovi\u0107 J, Milovanovi\u0107 J, Greenman, Marko Radulovic. The prognostic significance of serum interferon-gamma (IFN-\u03b3) in hormonally dependent breast cancer[J]. Cytokine. 2022;152:155836.","journal-title":"Cytokine"},{"issue":"6","key":"2106_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/biom15060761","volume":"15","author":"X Li","year":"2025","unstructured":"Li X, Zou C, Xiang X, Zhao L, Chen M, Yang C. Yu Wu. Myelodysplastic neoplasms (MDS): pathogenesis and therapeutic prospects. Biomolecules. 2025;15(6):761.","journal-title":"Biomolecules"},{"issue":"16","key":"2106_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164116","volume":"13","author":"A Syed","year":"2021","unstructured":"Syed A, Mian D. Nature or nurture? Role of the bone marrow microenvironment in the genesis and maintenance of myelodysplastic syndromes. Cancers. 2021;13(16):4116.","journal-title":"Cancers"},{"issue":"2","key":"2106_CR5","first-page":"330","volume":"110","author":"AMA Merz","year":"2024","unstructured":"Merz AMA, Platzbecker U. Treatment of lower-risk myelodysplastic syndromes. Haematologica. 2024;110(2):330\u20138.","journal-title":"Haematologica"},{"issue":"12","key":"2106_CR6","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00262-019-02420-x","volume":"68","author":"M\u00f3nica Paola Montes","year":"2019","unstructured":"Paola Montes M\u00f3nica, Bernal LN, Campo. Amanda Roc\u00edo Gonz\u00e1lez-Ram\u00edrez, Pilar Jim\u00e9nez, Pilar Garrido, Manuel Jurado, Federico Garrido, Francisco Ruiz-Cabello, Francisca Hern\u00e1ndez. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression[J]. Cancer Immunol Immunotherapy: CII. 2019;68(12):2015\u201327.","journal-title":"Cancer Immunol Immunotherapy: CII"},{"issue":"1","key":"2106_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Si Shi. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"key":"2106_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231183330","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Yang X, Ma L, Zhang Y. Immune dysregulation and potential targeted therapy in myelodysplastic syndrome. Ther Adv Hematol. 2023;14:20406207231183330.","journal-title":"Ther Adv Hematol"},{"key":"2106_CR9","doi-asserted-by":"crossref","unstructured":"Yinglong Wang X, Xiao H, Zheng J, Bai L, Li L, Zhang. The discussion on the differences in immune microenvironment between low-risk and high-risk myelodysplastic syndromes and acute myeloid leukemia[J]. Volume 66. Leukemia & Lymphoma; 2025. pp. 2397\u2013412. 13.","DOI":"10.1080\/10428194.2025.2549519"},{"key":"2106_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.blre.2019.04.004","volume":"36","author":"T Banerjee","year":"2019","unstructured":"Banerjee T, Calvi LM, Becker MW, Liesveld JL. Flaming and fanning: the spectrum of inflammatory influences in myelodysplastic syndromes. Blood Rev. 2019;36:57\u201369.","journal-title":"Blood Rev"},{"issue":"15","key":"2106_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2018-03-784116","volume":"132","author":"L Barreyro","year":"2018","unstructured":"Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132(15):1553\u201360.","journal-title":"Blood"},{"issue":"10","key":"2106_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1182\/blood-2018-10-844639","volume":"133","author":"E Pronk","year":"2019","unstructured":"Pronk E, Raaijmakers MHGP. The mesenchymal niche in MDS. Blood. 2019;133(10):1031\u20138.","journal-title":"Blood"},{"key":"2106_CR13","doi-asserted-by":"crossref","unstructured":"Xingcheng Yang L, Ma X, Zhang L, Huang J, Wei. Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia[J]. Volume 11. Experimental Hematology & Oncology; 2022. p. 11. 1.","DOI":"10.1186\/s40164-022-00263-4"},{"key":"2106_CR14","doi-asserted-by":"crossref","unstructured":"David A, Sallman A. List. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes[J]. Blood, 2019, 133(10): 1039\u20131048.","DOI":"10.1182\/blood-2018-10-844654"},{"issue":"4","key":"2106_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/leu.2017.326","volume":"32","author":"Y Mei","year":"2018","unstructured":"Mei Y, Zhao B, Basiorka AA, Yang J, Cao L, Zhang J, et al. Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS. Leukemia. 2018;32(4):1023\u201333.","journal-title":"Leukemia"},{"key":"2106_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02845-0","volume":"16","author":"H Zheng","year":"2025","unstructured":"Zheng H, Meng Z, Zhang L, Li L. Analysis of the differences in immune indexes of common gene mutations and 5q- chromosome karyotype mutations in MDS. Discov Oncol. 2025;16:1033.","journal-title":"Discov Oncol"},{"issue":"1","key":"2106_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01647-1","volume":"11","author":"K Syed","year":"2020","unstructured":"Syed K, Naguib S, Liu ZJ, Cimmino L, Yang FC. Novel combinations to improve hematopoiesis in myelodysplastic syndrome. Stem Cell Res Ther. 2020;11(1):132.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"2106_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00948-w","volume":"28","author":"Z Liu","year":"2023","unstructured":"Liu Z, Xu X, Zheng L, Ding K, Yang C, Huang J, et al. The value of serum IL-4 to predict the survival of MDS patients. Eur J Med Res. 2023;28(1):7.","journal-title":"Eur J Med Res"},{"issue":"10","key":"2106_CR19","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1016\/j.ymthe.2022.01.046","volume":"30","author":"Z Xu","year":"2022","unstructured":"Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. 2022;30(10):3133\u201354.","journal-title":"Mol Ther"},{"issue":"1","key":"2106_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0991-5","volume":"18","author":"L Mashouri","year":"2019","unstructured":"Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75.","journal-title":"Mol Cancer"},{"issue":"1","key":"2106_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","volume":"30","author":"I Vitale","year":"2019","unstructured":"Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 2019;30(1):36\u201350.","journal-title":"Cell Metab"},{"key":"2106_CR22","doi-asserted-by":"publisher","unstructured":"He Z, Zhang S. Tumor-associated macrophages and their functional transformation in the hypoxic tumor microenvironment. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.741305.","DOI":"10.3389\/fimmu.2021.741305"},{"issue":"1","key":"2106_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.immuni.2020.06.008","volume":"53","author":"A Bellomo","year":"2020","unstructured":"Bellomo A, Mondor I, Spinelli L, Lagueyrie M, Stewart BJ, Brouilly N, et al. Reticular fibroblasts expressing the transcription factor WT1 define a stromal niche that maintains and replenishes splenic red pulp macrophages. Immunity. 2020;53(1):127-142.e7.","journal-title":"Immunity"},{"key":"2106_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9913382","volume":"2021","author":"G Zhang","year":"2021","unstructured":"Zhang G, Yang L, Han Y, Niu H, Li Y, Shao Z. Abnormal macrophage polarization in patients with myelodysplastic syndrome. Mediators Inflamm. 2021;2021:9913382.","journal-title":"Mediators Inflamm"},{"issue":"23","key":"2106_CR25","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1182\/blood-2009-11-253534","volume":"116","author":"IG Winkler","year":"2010","unstructured":"Winkler IG, Sims NA, Pettit AR, Barbier V, Nowlan B, Helwani F, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood. 2010;116(23):4815\u201328.","journal-title":"Blood"},{"issue":"7","key":"2106_CR26","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/j.apsb.2024.03.004","volume":"14","author":"HE Shin","year":"2024","unstructured":"Shin HE, Han JH, Shin S, Bae GH, Son B, Kim TH, et al. M1-polarized macrophage-derived cellular nanovesicle-coated lipid nanoparticles for enhanced cancer treatment through hybridization of gene therapy and cancer immunotherapy. Acta Pharm Sin B. 2024;14(7):3169\u201383.","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"2106_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19082208","volume":"19","author":"YC Koh","year":"2018","unstructured":"Koh YC, Yang G, Lai CS, Weerawatanakorn M, Pan MH. Chemopreventive effects of phytochemicals and medicines on M1\/M2 polarized macrophage role in inflammation-related diseases. Int J Mol Sci. 2018;19(8):2208.","journal-title":"Int J Mol Sci"},{"key":"2106_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422355","volume":"15","author":"Z Nie","year":"2024","unstructured":"Nie Z, Fan Q, Jiang W, Wei S, Luo R, Hu H, et al. Placental mesenchymal stem cells suppress inflammation and promote M2-like macrophage polarization through the IL-10\/STAT3\/NLRP3 axis in acute lung injury. Front Immunol. 2024;15:1422355.","journal-title":"Front Immunol"},{"key":"2106_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01643","volume":"10","author":"Z Zong","year":"2019","unstructured":"Zong Z, Zou J, Mao R, Ma C, Li N, Wang J, et al. M1 macrophages induce PD-L1 expression in hepatocellular carcinoma cells through IL-1\u03b2 signaling. Front Immunol. 2019;10:1643.","journal-title":"Front Immunol"},{"key":"2106_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cytogfr.2018.01.007","volume":"39","author":"SF Valilou","year":"2018","unstructured":"Valilou SF, Keshavarz-Fathi M, Silvestris N, Argentiero A, Rezaei N. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine Growth Factor Rev. 2018;39:46\u201361.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"2106_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01328-x","volume":"15","author":"W Li","year":"2022","unstructured":"Li W, Wang F, Guo R, Bian Z, Song Y. Targeting macrophages in hematological malignancies: recent advances and future directions. J Hematol Oncol. 2022;15(1):110.","journal-title":"J Hematol Oncol"},{"key":"2106_CR32","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3389\/fonc.2019.01380","volume":"9","author":"P Mark","year":"2020","unstructured":"Mark P, Chao CH, Takimoto DD, Feng K, McKenna P, Gip J, Liu JP, Volkmer, Irving L, Weissman. Ravindra Majeti. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies[J]. Front Oncol. 2020;9:1380.","journal-title":"Front Oncol"},{"issue":"1","key":"2106_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/14712598.2020.1685976","volume":"20","author":"R Uger","year":"2020","unstructured":"Uger R, Johnson L. Blockade of the CD47-SIRP\u03b1 axis: a promising approach for cancer immunotherapy. Expert Opin Biol Ther. 2020;20(1):5\u20138.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"2106_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s10238-025-01915-5","volume":"25","author":"S Wajahat Mirza","year":"2025","unstructured":"Wajahat Mirza S, Dadan E, Ahmad A, Junaid. Tariq Mahmood Satti. Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: a systematic review of monoclonal antibodies and fusion proteins in combination strategies[J]. Clin Experimental Med. 2025;25(1):360.","journal-title":"Clin Experimental Med"},{"key":"2106_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.753092","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang H, Zheng X, Liu B, Xia Y, Xin Z, Deng B, et al. Aspartate metabolism facilitates IL-1\u03b2 production in inflammatory macrophages. Front Immunol. 2021;12:753092.","journal-title":"Front Immunol"},{"key":"2106_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01866","volume":"11","author":"S Chen","year":"2020","unstructured":"Chen S, Xia Y, He F, Fu J, Xin Z, Deng B, et al. Serine supports IL-1\u03b2 production in macrophages through mTOR signaling. Front Immunol. 2020;11:1866.","journal-title":"Front Immunol"},{"issue":"15","key":"2106_CR37","doi-asserted-by":"publisher","first-page":"eabe9274","DOI":"10.1126\/sciadv.abe9274","volume":"7","author":"Y Xia","year":"2021","unstructured":"Xia Y, He F, Wu X, Tan B, Chen S, Liao Y, Qi M, Chen S, Peng Y. Yulong Yin, Wenkai Ren. GABA transporter sustains IL-1\u03b2 production in macrophages[J]. Sci Adv. 2021;7(15):eabe9274.","journal-title":"Sci Adv"},{"key":"2106_CR38","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.molimm.2021.10.011","volume":"140","author":"Y Lin Xin","year":"2021","unstructured":"Lin Xin Y, Wu C, Liu F, Zeng JL, Wang DZ, Wu JP, Wu. Zhen Qi Yue, Jin Heng Gan, Hao Lu, Yi Wu Yuan, Li Qiang Zhou. Exosome-mediated transfer of lncRNA HCG18 promotes M2 macrophage polarization in gastric cancer[J]. Mol Immunol. 2021;140:196\u2013205.","journal-title":"Mol Immunol"},{"issue":"2","key":"2106_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086933","volume":"9","author":"Y Kim","year":"2014","unstructured":"Kim Y, Cheong JW, Kim YK, Kim JI, Hwang D, Kim JS. Serum microrna-21 as a potential biomarker for response to hypomethylating agents in myelodysplastic syndromes. PLoS One. 2014;9(2):e86933.","journal-title":"PLoS One"},{"key":"2106_CR40","doi-asserted-by":"crossref","unstructured":"Antonella Caivano FL, Rocca V, Simeon M, Girasole S, Dinarelli I, Laurenzana A, De Stradis. Luciana De Luca, Stefania Trino, Antonio Traficante, Giovanni D\u2019Arena, Giovanna Mansueto, Oreste Villani, Giuseppe Pietrantuono, Luca Laurenti, Luigi Del Vecchio, Pellegrino Musto. MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report[J]. Cellular Oncology (Dordrecht, Netherlands), 2017, 40(1): 97\u2013103.","DOI":"10.1007\/s13402-016-0300-x"},{"issue":"3","key":"2106_CR41","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.7150\/thno.52197","volume":"11","author":"Z Lijian","year":"2021","unstructured":"Lijian Z, Xiaoqing Z, P\u00e4ivi K, Thomas K, Anna K, Merja H-S, et al. Intravenous transplantation of olfactory ensheathing cells reduces neuroinflammation after spinal cord injury via interleukin-1 receptor antagonist. Theranostics. 2021;11(3):1147\u201361.","journal-title":"Theranostics"},{"issue":"9","key":"2106_CR42","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/infdis\/jiab165","volume":"224","author":"H Pyae","year":"2021","unstructured":"Pyae H, Htay A, Bohm K, Phyu T N, Thar Sann O, Sindhu M, et al. Endotoxin acts synergistically with Clostridioides difficile toxin B to increase interleukin 1\u03b2 production: a potential role for the intestinal biome in modifying the severity of C. difficile colitis. J Infect Dis. 2021;224(9):1556\u201365.","journal-title":"J Infect Dis"},{"issue":"8","key":"2106_CR43","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1038\/s41375-023-01949-2","volume":"37","author":"S Marie","year":"2023","unstructured":"Marie S, Clara R, Matthias T, Susann W, Luise F, Mandy R, et al. Activation of distinct inflammatory pathways in subgroups of LR-MDS. Leukemia. 2023;37(8):1709\u201318.","journal-title":"Leukemia"},{"issue":"6","key":"2106_CR44","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200560","volume":"218","author":"H Kelly C","year":"2021","unstructured":"Kelly C H, Andrew G, James S C, Marco DD, Etienne D, Vadym Z, et al. Chronic interleukin-1 exposure triggers selection for Cebpa -knockout multipotent hematopoietic progenitors. J Exp Med. 2021;218(6):e20200560.","journal-title":"J Exp Med"},{"issue":"3","key":"2106_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcyt.2020.01.001","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, Sun X, Yuan S, Hou S, Guo T, Chu Y, et al. Interleukin-1\u03b2 inhibits normal hematopoietic expansion and promotes acute myeloid leukemia progression via the bone marrow niche. Cytotherapy. 2020;22(3):127\u201334.","journal-title":"Cytotherapy"},{"issue":"9","key":"2106_CR46","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1080\/2162402X.2021.1944538","volume":"224","author":"H Grauers Wiktorin","year":"2021","unstructured":"Grauers Wiktorin H, Aydin E, Christenson K, Issdisai N, Thor\u00e9n F, Hellstrand K, et al. Impact of IL-1\u03b2 and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance. Oncoimmunology. 2021. https:\/\/doi.org\/10.1080\/2162402X.2021.1944538.","journal-title":"Oncoimmunology"},{"key":"2106_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.lfs.2016.09.019","volume":"165","author":"Y Congcong","year":"2016","unstructured":"Congcong Y, Na H, Peng L, Chen Z, Jie Y, Mingqiang H, et al. Polymorphisms of Interlukin-1\u03b2 rs16944 confer susceptibility to myelodysplastic syndromes. Life Sci. 2016;165:109\u201312.","journal-title":"Life Sci"},{"issue":"3","key":"2106_CR48","first-page":"937","volume":"26","author":"L Ying","year":"2018","unstructured":"Ying L, Qing Ping G, Bai Xin Y. [Research Progress on the Role of Pyroptosis in the Pathogenesis of Myelodysplastic Syndrome -Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26(3):937\u201341.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"21","key":"2106_CR49","doi-asserted-by":"publisher","first-page":"9626","DOI":"10.18632\/aging.102409","volume":"11","author":"S Lei","year":"2019","unstructured":"Lei S, Youshan Z, Chengming F, Juan G, Yan J, Dong W, et al. Cellular senescence induced by S100A9 in mesenchymal stromal cells through NLRP3 inflammasome activation. Aging. 2019;11(21):9626\u201342.","journal-title":"Aging"},{"key":"2106_CR50","doi-asserted-by":"crossref","unstructured":"Elia A-C, Demichelis-G\u00f3mez R, Rosas-L\u00f3pez A, Nancy R, Mej\u00eda-Dom\u00ednguez I, Galvan-L\u00f3pez M, Addorosio KJ, Tracey. Sergio Iv\u00e1n Vald\u00e9s-Ferrer. Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study[J]. Volume 13. Therapeutic Advances in Hematology; 2022. p. 20406207221125990.","DOI":"10.1177\/20406207221125990"},{"issue":"25","key":"2106_CR51","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1182\/blood-2016-07-730556","volume":"128","author":"A Ashley","year":"2016","unstructured":"Ashley A, Basiorka KL, McGraw EA, Eksioglu X, Chen J, Johnson L, Zhang Q, Zhang, Brittany A, Irvine T, Cluzeau DA, Sallman E, Padron R, Komrokji L, Sokol, Rebecca C, Coll, Avril AB, Robertson MA, Cooper JL, Cleveland. Luke A O\u2019Neill, Sheng Wei, Alan F List. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype[J]. Blood. 2016;128(25):2960\u201375.","journal-title":"Blood"},{"key":"2106_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00280","volume":"8","author":"EK Richard","year":"2018","unstructured":"Richard EK. Inhibiting the NLRP3 inflammasome with methylene blue as treatment adjunct in myelodysplasia. Front Oncol. 2018;8:280.","journal-title":"Front Oncol"},{"issue":"7","key":"2106_CR53","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/07357907.2019.1638395","volume":"37","author":"C Simondurairaj","year":"2019","unstructured":"Simondurairaj C, Krishnakumar R, Sundaram S, Venkatraman G. Interleukin-6 receptor (IL-6R) expression in human gastric carcinoma and its clinical significance. Cancer Invest. 2019;37(7):293\u20138.","journal-title":"Cancer Invest"},{"issue":"1","key":"2106_CR54","doi-asserted-by":"publisher","first-page":"15584","DOI":"10.1038\/ncomms15584","volume":"8","author":"P Hasini Jayatilaka","year":"2017","unstructured":"Hasini Jayatilaka P, Tyle JJ, Chen M, Kwak J, Ju HJ, Kim, Jerry SH, Lee PH, Wu, Daniele M, Gilkes. Rong Fan, Denis Wirtz. Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration[J]. Nat Commun. 2017;8(1):15584.","journal-title":"Nat Commun"},{"issue":"8","key":"2106_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09953","volume":"8","author":"Y Xi","year":"2022","unstructured":"Xi Y, Han L, Zhao R, Fatima S, Zhao L, Gao F. Prognosis value of IL-6, IL-8, and IL-1\u03b2 in serum of patients with lung cancer: a fresh look at interleukins as a biomarker. Heliyon. 2022;8(8):e09953.","journal-title":"Heliyon"},{"issue":"3","key":"2106_CR56","doi-asserted-by":"publisher","first-page":"e12776","DOI":"10.1111\/cpr.12776","volume":"53","author":"H Wen Liu","year":"2020","unstructured":"Wen Liu H, Wang F, Bai L, Ding Y, Huang C, Lu S, Chen C, Li X, Yue X, Liang C, Ma L, Xu L, Gao. IL-6 promotes metastasis of non\u2010small\u2010cell lung cancer by up\u2010regulating TIM\u20104 via NF\u2010\u03baB[J]. Cell Prolif. 2020;53(3):e12776.","journal-title":"Cell Prolif"},{"key":"2106_CR57","doi-asserted-by":"crossref","unstructured":"Xiwei Wang Z, Xiang GSW, Tsao, Wenwei Tu. Exosomes derived from nasopharyngeal carcinoma cells induce IL-6 production from macrophages to promote tumorigenesis[J]. Volume 18. Cellular & Molecular Immunology; 2021. pp. 501\u20133. 2.","DOI":"10.1038\/s41423-020-0420-0"},{"key":"2106_CR58","doi-asserted-by":"crossref","first-page":"155617","DOI":"10.1016\/j.cyto.2021.155617","volume":"148","author":"Luciana de Brito Falc\u00e3o","year":"2021","unstructured":"Luciana de Brito Falc\u00e3o. Anac\u00e9lia Gomes de Matos, Deysi Viviana Tenazoa Wong, Roberto C\u00e9sar Pereira Lima-J\u00fanior, Priscila da Silva Mendon\u00e7a, Ana Patr\u00edcia Nogueira Aguiar, Roberta Taiane Germano de Oliveira, Emanna Od\u00edlia de Castro Lima, Ronald Feitosa Pinheiro, S\u00edlvia Maria Meira Magalh\u00e3es. Plasma IL-33 levels are decreased in patients with high-risk myelodysplastic syndrome and show no correlation with pro-inflammatory IL-6 levels[J]. Cytokine. 2021;148:155617.","journal-title":"Cytokine"},{"key":"2106_CR59","doi-asserted-by":"crossref","unstructured":"Yang Mei K, Ren Y, Liu A, Ma Z, Xia X, Han E, Li H, Tariq H, Bao X, Xie C, Zou D, Zhang Z, Li L, Dong A, Verma X, Lu Y, Abaza, Jessica K, Altman M, Sukhanova J, Yang P. Ji. Bone marrow\u2013confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia[J]. Journal of Clinical Investigation, 2022, 132(17): e152673.","DOI":"10.1172\/JCI152673"},{"issue":"9","key":"2106_CR60","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1002\/1878-0261.12737","volume":"14","author":"J Zhang","year":"2020","unstructured":"Zhang J, Jiang M, Qian L, Lin X, Song W, Gao Y. The STAT3-miR\u2010223\u2010TGFBR3\/HMGCS1 axis modulates the progression of cervical carcinoma. Mol Oncol. 2020;14(9):2313\u201331.","journal-title":"Mol Oncol"},{"issue":"1","key":"2106_CR61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.htct.2019.12.002","volume":"43","author":"L Matilde Boada","year":"2021","unstructured":"Matilde Boada L, Echarte C, Guillermo Lili\u00e1n, Diaz. Cristina Touri\u00f1o, Sof\u00eda Grille. 5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients[J]. Hematol Transfus Cell Therapy. 2021;43(1):35\u201342.","journal-title":"Hematol Transfus Cell Therapy"},{"issue":"20","key":"2106_CR62","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","volume":"125","author":"O Carolina Schinke","year":"2015","unstructured":"Carolina Schinke O, Giricz W, Li A, Shastri S, Gordon L, Barreyro T, Bhagat S, Bhattacharyya N, Ramachandra M, Bartenstein A, Pellagatti J, Boultwood. Amittha Wickrema, Yiting Yu, Britta Will, Sheng Wei, Ulrich Steidl, Amit Verma. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells[J]. Blood. 2015;125(20):3144.","journal-title":"Blood"},{"issue":"4","key":"2106_CR63","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/bjc.2017.414","volume":"118","author":"S Ahmad","year":"2018","unstructured":"Ahmad S, Khazali AM, Clark A, Wells. Inflammatory cytokine IL-8\/CXCL8 promotes tumour escape from hepatocyte-induced dormancy[J]. Br J Cancer. 2018;118(4):566\u201376.","journal-title":"Br J Cancer"},{"key":"2106_CR64","doi-asserted-by":"crossref","unstructured":"Kobe C, Yuen LF, Liu V, Gupta S, Madireddi S, Keerthivasan C, Li D, Rishipathak P, Williams EE, Kadel H, Koeppen YJ, Chen Z, Modrusan JL, Grogan S, Van Der Heijden JE, Rosenberg DF, McDermott T, Powles, Priti S, Hegde MA, Huseni, Sanjeev Mariathasan. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade[J]. Nature Medicine, 2020, 26(5): 693\u2013698.","DOI":"10.1038\/s41591-020-0860-1"},{"key":"2106_CR65","doi-asserted-by":"crossref","unstructured":"Anac\u00e9lia G, de Matos HLR, Junior. Daniela de Paula Borges, Bruno Mem\u00f3ria Okubo, Juliana Cordeiro de Sousa, Maritza Cavalcante Barbosa, Marilena Facundo de Castro, Rom\u00e9lia Pinheiro Gon\u00e7alves, Ronald Feitosa Pinheiro, Silvia Maria Meira Magalh\u00e3es. Interleukin-8 and nuclear factor kappa B are increased and positively correlated in myelodysplastic syndrome[J]. Volume 34. London, England: Medical Oncology (Northwood; 2017. p. 168. 10.","DOI":"10.1007\/s12032-017-1023-1"},{"issue":"15suppl","key":"2106_CR66","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2018.36.15_suppl.3025","volume":"36","author":"M Carleton","year":"2018","unstructured":"Carleton M, Zhou M, Henau OD, Phillips P, Chen T, Feng Y, Huang SP, Walsh A, Timothy P, Reilly. Ignacio Melero Bermejo. Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.[J]. J Clin Oncol. 2018;36(15suppl):3025\u20133025.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2106_CR67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1755-7682-3-11","volume":"3","author":"A Shahzad","year":"2010","unstructured":"Shahzad A, Knapp M. Irene Lang, Gottfried K\u00f6hler. Interleukin 8 (IL-8) - a universal biomarker?[J]. Int Archives Med. 2010;3(1):11.","journal-title":"Int Archives Med"},{"issue":"5","key":"2106_CR68","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.immuni.2014.03.012","volume":"40","author":"B Ehud Zigmond","year":"2014","unstructured":"Ehud Zigmond B, Bernshtein G, Friedlander CR, Walker S, Yona KW, Kim O, Brenner R, Krauthgamer C, Varol. Werner M\u00fcller, Steffen Jung. Macrophage-Restricted Interleukin-10 Receptor Deficiency, but Not IL-10 Deficiency, Causes Severe Spontaneous Colitis[J]. Immunity. 2014;40(5):720\u201333.","journal-title":"Immunity"},{"issue":"3","key":"2106_CR69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/ejh.12577","volume":"96","author":"T Tetsuhiro Kasamatsu","year":"2016","unstructured":"Tetsuhiro Kasamatsu T, Saitoh Y, Minato H, Shimizu A, Yokohama N, Tsukamoto H, Handa. Toru Sakura, Hirokazu Murakami. Polymorphisms of IL-10 affect the severity and prognosis of myelodysplastic syndrome[J]. Eur J Haematol. 2016;96(3):245\u201351.","journal-title":"Eur J Haematol"},{"key":"2106_CR70","doi-asserted-by":"crossref","unstructured":"Peter Hsu B, Santner-Nanan M, Hu K, Skarratt CH, Lee M, Stormon M, Wong SJ, Fuller R, Nanan. IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1[J]. Journal of Immunology (Baltimore, Md.: 1950), 2015, 195(8): 3665\u20133674.","DOI":"10.4049\/jimmunol.1402898"},{"issue":"4","key":"2106_CR71","doi-asserted-by":"publisher","first-page":"733","DOI":"10.4103\/ejim.ejim_37_19","volume":"31","author":"E Alaa E Hassan","year":"2019","unstructured":"Alaa E Hassan E, Marwa Tahoon M, Hanan Bediera H. Study of proinflammatory and anti-inflammatory states in myelodysplastic syndrome patients. Egypt J Intern Med. 2019;31(4):733\u201340.","journal-title":"Egypt J Intern Med"},{"issue":"1","key":"2106_CR72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","volume":"145","author":"S Kordasti","year":"2009","unstructured":"Kordasti S, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145(1):64\u201372.","journal-title":"Br J Haematol"},{"issue":"8","key":"2106_CR73","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1177\/1753425920961157","volume":"26","author":"D Dong Han","year":"2020","unstructured":"Dong Han D, Jinglian Tao J, Rong Fu R, Zonghong Shao Z. Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes. Innate Immun. 2020;26(8):703\u201315.","journal-title":"Innate Immun"},{"key":"2106_CR74","doi-asserted-by":"crossref","unstructured":"Eddie Ip WK, Hoshi N, Dror S, Shouval S, Snapper R, Medzhitov. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages[J]. Volume 356. Science; 2017. pp. 513\u20139. (New York, N.Y.). 6337.","DOI":"10.1126\/science.aal3535"},{"key":"2106_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2023.156312","volume":"170","author":"Y Yu Xin Fan","year":"2023","unstructured":"Yu Xin Fan Y, Li Rong Chen L, Run Xin Gan R, Sun Jun Yin S, Ping Wang P, Rui Meng R, et al. A meta-analysis of associations of IL-10 gene polymorphisms with acute leukemia susceptibility. Cytokine. 2023;170:156312.","journal-title":"Cytokine"},{"issue":"1","key":"2106_CR76","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4238\/2015.February.2.15","volume":"14","author":"C C Fei","year":"2015","unstructured":"C Fei C, X M Yao X, Y Sun Y, X Z Gu X, L Q Yu L, X Lai X. Interleukin-10 polymorphisms associated with susceptibility to acute myeloid leukemia. Genet Mol Res. 2015;14(1):925\u201330.","journal-title":"Genet Mol Res"},{"issue":"5","key":"2106_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052719","volume":"22","author":"D Dan in Jang","year":"2021","unstructured":"Dan in Jang D, A Hyeon Lee A, Hye Yoon Shin H, Hyo Ryeong Song H, Jong Hwi Park J, Tae Bong Kang T, et al. The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2106_CR78","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1111\/febs.14182","volume":"284","author":"V Vladimir N Uversky","year":"2017","unstructured":"Vladimir N Uversky V, Nawal Abd El-Baky N, Esmail M El-Fakharany E, Amira Sabry A, Ehab H Mattar E, Alexey V Uversky A, et al. Functionality of intrinsic disorder in tumor necrosis factor-\u03b1 and its receptors. FEBS J. 2017;284(21):3589\u2013618.","journal-title":"FEBS J"},{"issue":"Suppl","key":"2106_CR79","first-page":"135","volume":"3","author":"A David","year":"2019","unstructured":"David A, Sallman A. The role of innate immunity in MDS pathogenesis[J]. HemaSphere. 2019;3(Suppl):135\u20137.","journal-title":"HemaSphere"},{"issue":"1","key":"2106_CR80","first-page":"1046","volume":"26","author":"Z Tao","year":"2021","unstructured":"Tao Z, Yin SJ, Wang P, Li YXFZR, Yang Q, Huang YH, et al. Association between TNF-\u03b1 gene polymorphisms and susceptibility of myelodysplastic syndromes: a meta-analysis. Hematol (Amsterdam Netherlands). 2021;26(1):1046\u201356.","journal-title":"Hematol (Amsterdam Netherlands)"},{"issue":"12","key":"2106_CR81","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.bbmt.2010.06.003","volume":"16","author":"F Laura","year":"2010","unstructured":"Laura F, Newell T, Gooley JA, Hansen DL, Stirewalt, Effie W, Petersdorf H, Joachim, Deeg. Tumor necrosis factor polymorphism affects transplantation outcome in patients with myelodysplastic syndrome but not in those with chronic myelogenous leukemia, independent of the presence of HLA-DR15[J]. Biology of Blood and Marrow Transplantation. J Am Soc Blood Marrow Transplantation. 2010;16(12):1700\u20136.","journal-title":"J Am Soc Blood Marrow Transplantation"},{"key":"2106_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00847","volume":"9","author":"C Fl\u00e1via","year":"2018","unstructured":"Fl\u00e1via C, Ana PC, Raquel MG, Karine S, Maria JO. Interferon-Gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol. 2018;9:847.","journal-title":"Front Immunol"},{"issue":"19","key":"2106_CR83","doi-asserted-by":"publisher","first-page":"7178","DOI":"10.3390\/ijms21197178","volume":"21","author":"AS Heimes","year":"2020","unstructured":"Heimes AS, H\u00e4rtner F, Almstedt K, Krajnak S, Lebrecht A, Marco J, Battista K, Edlund W, Brenner A, Hasenburg U, Sahin M, Gehrmann, Jan G, Hengstler M, Schmidt. Prognostic Significance of Interferon-\u03b3 and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes[J]. Int J Mol Sci. 2020;21(19):7178.","journal-title":"Int J Mol Sci"},{"key":"2106_CR84","doi-asserted-by":"crossref","unstructured":"Huihui Ding G, Wang Z, Yu H, Sun L. Wang. Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1\/2 (IFN\u03b3R1\/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway[J]. Volume 155. Biomedicine & Pharmacotherapy; 2022. p. 113683.","DOI":"10.1016\/j.biopha.2022.113683"},{"issue":"1","key":"2106_CR85","doi-asserted-by":"publisher","first-page":"11697","DOI":"10.1038\/s41598-019-48256-4","volume":"9","author":"DY-EG Tunali","year":"2019","unstructured":"Tunali DY-EG, Tavukcuoglu E, Horzum U, Ozkazanc D, Sutlu T. Yahya Buyukasik, Gunes Esendagli. Myeloid maturation potentiates STAT3-mediated atypical IFN-\u03b3 signaling and upregulation of PD-1 ligands in AML and MDS[J]. Sci Rep. 2019;9(1):11697.","journal-title":"Sci Rep"},{"key":"2106_CR86","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-med-051914-021329","volume":"67","author":"V Krishna","year":"2016","unstructured":"Krishna V, Komanduri, Ross L, Levine. Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification[J]. Annu Rev Med. 2016;67:59\u201372.","journal-title":"Annu Rev Med"},{"issue":"21","key":"2106_CR87","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1182\/blood-2010-04-280123","volume":"117","author":"S Michele","year":"2011","unstructured":"Michele S, Redell MJ, Ruiz TA, Alonzo RB, Gerbing DJ, Tweardy. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor[J]. Blood. 2011;117(21):5701.","journal-title":"Blood"},{"key":"2106_CR88","doi-asserted-by":"crossref","unstructured":"Axel R\u00fcfer H, Angermann R, Benz N, Bonadies A, Calderoni N, Cantoni A, Efthymiou R, Escher Genevi\u00e8ve, Favre D, Friess A, Gschwend A, Himmelmann A, Holbro P, Keller E, Kouroupi T, Lehmann A, Schmidt HP, Sch\u00e4fer R, Sperb G, St\u00fcssi A, Winkler R, Zenh\u00e4usern, Jeroen S. Goede, on behalf of the SLIM-Registry Investigators. Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)\u2014Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)[J]. HemaSphere, 2022, 6(7): e741.","DOI":"10.1097\/HS9.0000000000000741"},{"issue":"4","key":"2106_CR89","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/nm.3512","volume":"20","author":"NVS Rajasekhar","year":"2014","unstructured":"Rajasekhar NVS, Suragani SM, Cadena SM, Cawley D, Sako D, Mitchell R, Li MV, Davies MJ, Alexander M, Devine KS, Loveday KW, Underwood, Asya V, Grinberg JD, Quisel R, Chopra RS. Pearsall, Jasbir Seehra, Ravindra Kumar. Transforming growth factor-\u03b2 superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis[J]. Nat Med. 2014;20(4):408\u201314.","journal-title":"Nat Med"},{"key":"2106_CR90","doi-asserted-by":"crossref","unstructured":"Pierre Fenaux U, Platzbecker GJ, Mufti G, Garcia-Manero R, Buckstein V, Santini Mar\u00eda, D\u00edez-Campelo C, Finelli M, Cazzola O, Ilhan, Mikkael A, Sekeres Jos\u00e9F, Falantes B, Arrizabalaga F, Salvi V, Giai P, Vyas D, Bowen D, Selleslag AE, DeZern, Joseph G, Jurcic U, Germing, Katharina S, G\u00f6tze E, Vellenga, Peter L, Greenberg DR, Dunshee, Peter G, Linde ML, Sherman RS, Komrokji. Alan F List. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes[J]. The New England Journal of Medicine, 2020, 382(2): 140\u2013151.","DOI":"10.1056\/NEJMoa1908892"},{"issue":"4","key":"2106_CR91","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41590-021-00895-4","volume":"22","author":"S Mahesh Raundhal","year":"2021","unstructured":"Mahesh Raundhal S, Ghosh SA, Myers MS, Cuoco M, Singer SA, Carr SS, Waikar JV, Bonventre J, Ritz RM, Stone. David P Steensma, Aviv Regev, Laurie H Glimcher. Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias[J]. Nat Immunol. 2021;22(4):520\u20139.","journal-title":"Nat Immunol"},{"issue":"3","key":"2106_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120602","volume":"10","author":"M Kim","year":"2015","unstructured":"Kim M, Hwang S, Park K, Kim SY, Lee YK, Lee DS. Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes. PLoS One. 2015;10(3):e0120602.","journal-title":"PLoS One"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02106-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:57:29Z","timestamp":1773896249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02106-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2106"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02106-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}